Loading...

Japanese Simple Chinese Traditional Chinese Korean 
Corporate Sponsors

almac

AB_SCIEX

ariadne new

Caprion

 Cirion

Covance

febit (New Logo)

FutureDiagnostics
Metanomicshealth

Meso Scale

Millipore (updated)

Quest Diagnostics
Quotient Bioresearch

Rules Based Medicine|

ThermoScientific

Thomson Scientific

Waters_Black_with_tagline

Corporate Support Sponsor

Aushon Biosystems

Lead Sponsoring Publications

Biomarkers in Medicine

Bio-IT-Word_logo

GEN_logo

International Drug Discovery

J_BiologicalMarkers

Nature_logo

Science AAAS

The Scientist


Additional Media Partners:










Loading...

DOWNLOADS

Biomarker World Congress 2010 Final BrochureBiomarker World Congress 2010 Final Brochure
The signature event in Cambridge Healthtech Institute’s Biomarker Series, the Biomarker World Congress 2010 is dedicated to all areas of biomarker research spanning the pharmaceutical and diagnostic pipeline. The meeting brings together a unique and international mix of large and medium pharmaceutical, biotech and diagnostics companies, leading universities and clinical research institutions, government and national labs, CROs, emerging companies and tool providers—making the Congress a perfect meeting place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies. The Congress also offers a balance of scientific sessions covering the latest research and strategic presentations and brainstorming sessions for the decision makers. Now in its sixth year, the Biomarker World Congress is the leading annual meeting dedicated to biomarker research and implementation that consistently delivers a cutting-edge agenda, 450+ senior delegates, and a sold-out exhibit hall.

Biomarker World Congress Conference at a Glance  BrochureBiomarker World Congress Conference at a Glance 











2009 Final Brochure CoverBiomarker World Congress 2009 Final Brochure 
Over 400 thought leaders from 200+ organizations, representing 21 countries, gathered at the Biomarker World Congress 2009 (May 27-29 in Philadelphia) to discuss the biomarker impact on Personalized Medicine, Clinical Pharmacology, Translational Medicine, Molecular Diagnostics, Safety Assessment, Clinical Trials, Assay Development, Go/No-Go Decision Making and Oncology in Drug & Diagnostics. The level of energy and participation reflected the booming interest in this field.

CHI would like to thank the scientific advisors, sponsors, and all of the participants for making this meeting another Biomarker & Diagnostic Series success!